Type 2 Diabetes Current and Future Medications: A Short Review
Journal: Journal of Pharmaceutical Research Science & Technology (Vol.1, No. 1)Publication Date: 2017-03-01
Authors : Jahangir MA Imam SS Kazmi I Muheem A;
Page : 1-6
Keywords : Diabetes Mellitus; Type 2 diabetes; USFDA;
Abstract
Diabetes Mellitus (DM) is a complex set of disease. It is basically a metabolic disorder in which body is unable to make enough insulin or it is not able to use insulin effectively or in some instances both. According to global report on diabetes released by World Health Organization, Geneva 422 million people suffers from diabetes in 2014. The number is expected to increase to 552 million by 2030. A number of researches are going on around the globe by pharmaceutical companies to exploit the huge market it provides. This short review covers the brief basics of DM and its classification medication. This review mainly focus on type 2 diabetes discussing the new classification of medication available in the market as well as the approved antidiabetic drugs for type 2 diabetes by USFDA after 2010 and the pipeline antidiabetic drugs under clinical trials. This short review article has been prepared reviewing data available from PubMed, National Institute of Health, USFDA, clinicaltrials.gov and other related sites
Other Latest Articles
- CONTRIBUTION OF EMOTIONAL INTELLIGENCE IN OUR EDUCATION SYSTEM
- Laboratory evaluation of four insecticides on the mosquito Culiseta longiareolata (Macquart) (Diptera Culicidae)
- Study of the effect of silver nanoparticles encapsulated by doxorubicin drug in the treatment of hepatocellular carcinoma
- Apoptotic Marker Alternations in the Spleen of Experimentally Hyperthyroid and Hypothyroid Rat
- Apoptotic Marker Alternations in the Spleen of Experimentally Hyperthyroid and Hypothyroid Rat
Last modified: 2018-01-21 18:22:20